CYTOKINETICS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CYTK$55.14+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $94,857 | $113,024 |
| Short-term investments | 981,157 | 501,800 |
| Accounts receivable | 16,650 | 1,283 |
| Prepaid expenses and other current assets | 15,276 | 11,944 |
| Total current assets | 1,107,940 | 628,051 |
| Long-term investments | 145,055 | 40,534 |
| Property and equipment, net | 65,815 | 68,748 |
| Operating lease right-of-use assets | 75,158 | 78,987 |
| Other assets | 7,705 | 7,996 |
| Total assets | $1,401,673 | $824,316 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $20,369 | $21,507 |
| Accrued liabilities | 55,323 | 42,641 |
| Short-term operating lease liabilities | 18,978 | 17,891 |
| Current portion of long-term debt | 11,520 | 10,080 |
| Derivative liabilities measured at fair value | 11,300 | — |
| Deferred revenue | 52,370 | — |
| Other current liabilities | 9,814 | 10,559 |
| Total current liabilities | 179,674 | 102,678 |
| Term loans, net | 93,227 | 58,384 |
| Convertible notes, net | 552,370 | 548,989 |
| Liabilities related to revenue participation right purchase agreements, net | 462,192 | 379,975 |
| Long-term operating lease liabilities | 112,582 | 120,427 |
| Liabilities related to RPI Transactions measured at fair value | 137,000 | — |
| Other non-current liabilities | — | 186 |
| Total liabilities | 1,537,045 | 1,210,639 |
| Commitments and contingencies | ||
| Stockholders' deficit | ||
| Preferred stock, $0.001 par value: | ||
| Authorized: 10,000,000 shares; Issued and outstanding: none | — | — |
| Common stock, $0.001 par value: | ||
| Authorized: 163,000,000 shares | ||
| Issued and outstanding: 118,209,139 shares at December 31, 2024 and 101,637,922 shares at December 31, 2023 | 118 | 102 |
| Additional paid-in capital | 2,563,876 | 1,725,823 |
| Accumulated other comprehensive income (loss) | 2,398 | (10) |
| Accumulated deficit | (2,701,764) | (2,112,238) |
| Total stockholders' deficit | (135,372) | (386,323) |
| Total liabilities and stockholders' deficit | $1,401,673 | $824,316 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.